Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRS3 | P32247 | 18/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14531621 | 1.00 | BRS3 (0.37) | BRS3HRH4JAK2JAK1 | |
| SCHEMBL1605510 | 1.00 | BRS3 (0.37) | BRS3HRH4JAK2JAK1 | |
| SCHEMBL14459717 | 1.00 | BRS3 (0.37) | BRS3HRH4JAK2JAK1 | |
| SCHEMBL1605514 | 1.00 | BRS3 (0.37) | BRS3HRH4JAK2JAK1 | |
| SCHEMBL1606680 | 0.90 | P2RX7 (0.39) | BRS3JAK2JAK1 | |
| SCHEMBL4402655 | 0.90 | P2RX7 (0.39) | BRS3JAK2JAK1 | |
| SCHEMBL14531136 | 0.90 | P2RX7 (0.39) | BRS3JAK2JAK1 | |
| SCHEMBL1606678 | 0.90 | P2RX7 (0.39) | BRS3JAK2JAK1 | |
| SCHEMBL14429404 | 0.88 | GABBR2 (0.38) | BRS3JAK2JAK1 | |
| SCHEMBL10284876 | 0.88 | HSP90AA1 (0.42) | BRS3HRH4JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951695-B1 | CATALYZED PROCESS OF MAKING C-5-SUBSTITUTED HETEROCYCLIC INHIBITORS OF 11ß-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7541474-B2 | Catalyzed process of making C-5-substituted heterocyclic inhibitors of 11β-hydroxy steroid dehydrogenase type 1 | AMGEN INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541474-B2 | Catalyzed process of making C-5-substituted heterocyclic inhibitors of 11β-hydroxy steroid dehydrogenase type 1 | AMGEN INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541474-B2 | Catalyzed process of making C-5-substituted heterocyclic inhibitors of 11β-hydroxy steroid dehydrogenase type 1 | AMGEN INC. (US) | 2009-06-02 | — | — | US | disclosed |
| EP-1951695-A1 | CATALYZED PROCESS OF MAKING C-5-SUBSTITUTED HETEROCYCLIC INHIBITORS OF 11ß-HYDROXY STEROID DEHYDROGENASE TYPE 1 | Amgen Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007061600-A1 | CATALYZED PROCESS OF MAKING C-5-SUBSTITUTED HETEROCYCLIC INHIBITORS OF 11ß-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070117985-A1 | Catalyzed process of making C-5-substituted heterocyclic inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 | AMGEN, INC. | 2007-05-24 | — | — | US | disclosed |
| US-20070117985-A1 | Catalyzed process of making C-5-substituted heterocyclic inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 | AMGEN, INC. | 2007-05-24 | — | — | US | disclosed |
| US-20070117985-A1 | Catalyzed process of making C-5-substituted heterocyclic inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 | AMGEN, INC. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117985-A1 | Catalyzed process of making C-5-substituted heterocyclic inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 | SRD5A1, HSD11B1, HSD3B1 | BRS3 2703/4885HRH4 1201/4885JAK2 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.